Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Chifotides, H. T., Masarova, L., Alfayez, M., Daver, N., Alvarado, Y., Jabbour, E., … Verstovsek, S. (2020). Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Advances, 4(21), 5336–5342. https://doi.org/10.1182/BLOODADVANCES.2020001528